11/06/2026
“This study underscores how metabolic vulnerabilities can be exploited to counter therapy resistance in Ewing sarcoma. Importantly, it highlights the promise of noninvasive metabolic imaging to track treatment-relevant biology and help guide therapy optimization,” said corresponding author Puneet Bagga, PhD, Department of Radiology. 💛
By examining causes of SLFN11 deficiency in recurrent Ewing sarcoma, scientists at St. Jude identified a metabolic process, glycerophospholipid biosynthesis, as a potential target to overcome chemoresistance in recurrent Ewing sarcoma.